2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-19889A
    JNJ-18038683 free base 851373-91-6 98%
    JNJ-18038683 free base is a 5-Hydroxytryptamine Type 7 (5-HT7) receptor antagonist, with pKis of 8.19, 8.20 for rat and human 5-HT7 in HEK293 cells, respectively.
    JNJ-18038683 free base
  • HY-19946A
    Eptapirone fumarate 179756-85-5 98%
    Eptapirone fumarate (F11440 fumarate) is a potent, selective and orally active 5-HT1A receptor agonist (pKi = 8.33). Eptapirone fumarate can inhibit cAMP production. Eptapirone fumarate can reduce 5-HT levels and increase corticosterone levels. Eptapirone fumarate shows potent anxiolytic and antidepressant potential. Eptapirone fumarate can be used for the research of neurological disease, such as anxiety and depression.
    Eptapirone fumarate
  • HY-202233
    Tetramethylpyrazine nitrone 1083171-75-8 98%
    Tetramethylpyrazine nitrone is a nitrone derivative of tetramethylpyrazine. Tetramethylpyrazine nitrone is an active ingredient from Ligusticum wallichii Franchat. Tetramethylpyrazine nitrone is a potent scavenger of free radicals with neuroprotective activitys in both rat and monkey models of ischemis stroke. Tetramethylpyrazine nitrone can suppress over-expression of neuroinflammatory marker vimentin.
    Tetramethylpyrazine nitrone
  • HY-204388
    TAK-137 1358749-55-9
    TAK-137 is an AMPA receptor potentiator with weak agonistic effect. TAK-137 binds to the AMPA receptor ligand binding domain in a glutamate-dependent manner. TAK-137 potentiates AMPA-induced currents and Ca2+ influx. TAK-137 can be used for the research of neurological disease.
    TAK-137
  • HY-21197S
    Perfluoroenanthic acid-13C4 2328024-55-9 98%
    Perfluoroenanthic acid-13C4 (Perfluoroheptanoic acid-13C4) is the 13C-labeled Perfluoroenanthic acid (HY-21197). Perfluoroenanthic acid (Perfluoroheptanoic acid) is a kind of perfluoroalkyl carboxylic acid organic pollutant. Perfluoroenanthic acid has environmental persistence and bioaccumulation, and exposure can occur via oral, dermal and other routes. Perfluoroenanthic acid exhibits reproductive toxicity, neurotoxicity, hepatotoxicity, immunotoxicity and endocrine-disrupting effects. Perfluoroenanthic acid exerts definite adverse effects on development, spermatogenesis, neuronal activity and liver tissue.
    Perfluoroenanthic acid-13C4
  • HY-22385A
    Salsolidine hydrochloride 63283-42-1 98%
    Salsolidine hydrochloride, a tetrahydroisoquinoline alkaloid, acts as a stereoselective competitive MAO A (monoamine oxidase A) inhibitor.
    Salsolidine hydrochloride
  • HY-22385B
    (S)-Salsolidine 493-48-1 98%
    (S)-Salsolidine is a weak monoamine oxidase (MAO) inhibitor (Ki=63 μM). The R enantiomer of Salsolidine is more potent than the S form (Ki=26 μM).
    (S)-Salsolidine
  • HY-22437S
    (±)-Darifenacin-d4 1189701-43-6 98%
    (±)-Darifenacin-d4 is deuterium labeled (±)-Darifenacin. (±)-Darifenacin is the racemate of Darifenacin. Darifenacin is a selective M3 muscarinic receptor antagonist.
    (±)-Darifenacin-d4
  • HY-30152R
    Xanthotoxol (Standard) 2009-24-7 98%
    Xanthotoxol (Standard) is the analytical standard of Xanthotoxol. This product is intended for research and analytical applications. Xanthotoxol (8-Hydroxypsoralen) It is a kind of fragrant bean substance, and it is a CYP450 inhibitor. Xanthotoxol has anti-inflammatory, anti-inflammatory, and 5-HT antagonistic and protective effects. Xanthotoxol inhibited CYP3A4 sum CYP1A2 IC50s separation 7.43 μM sum 27.82 μM. Xanthotoxol can pass through MAPK and NF-κB, inhibiting inflammation.
    Xanthotoxol (Standard)
  • HY-401209
    Synucleozid-2.0 613226-91-8 98%
    Synucleozid-2.0 is a blood-brain barrier-permeable inhibitor that binds to the IRE of SNCA mRNA, with a EC50 of 2.9 µM and a Kd value of 1.8 µM. Synucleozid-2.0 selectively binds to and stabilizes the A bulge and adjacent closed base pairs in the 5' UTR IRE of SNCA mRNA, blocks the translation process and reduces intracellular levels of α-synuclein. Synucleozid-2.0 exerts cytoprotective effects against cytotoxicity induced by α-synuclein preformed fibrils. Synucleozid-2.0 is applicable to the research of Parkinson's disease.
    Synucleozid-2.0
  • HY-402309
    IGF-1R modulator 1 2375424-89-6 98%
    IGF-1R modulator 1 (Example 5) is an IGF-1R modulator, with EC50s of 0.29 μM (FGFR1), 0.25 μM (IGF1R), 0.34 μM (TrkA), 0.39 μM (TrkB). IGF-1R modulator 1 can be used for research of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease.
    IGF-1R modulator 1
  • HY-402873
    DMTr-2'-O-C16-rC(Ac)-3'-CE-phosphoramidite 2382942-38-1
    DMTr-2'-O-C16-rC(Ac)-3'-CE-phosphoramidite (Compound 5) is an RNAi agent and an inhibitor of Ataxin-2 (ATXN2). DMTr-2'-O-C16-rC(Ac)-3'-CE-phosphoramidite can be studied in research on ATXN2-associated neurological diseases.
    DMTr-2'-O-C16-rC(Ac)-3'-CE-phosphoramidite
  • HY-404647
    FK3453 560111-91-3 98%
    FK3453 is a dual adenosine A1/A2 inhibitor and a TSLP inhibitor. FK3453 is also a substrate of aldehyde oxidase (AO). FK3453 can inhibit the production of TSLP and IL-33. FK3453 is useful for research on Parkinson’s disease and allergic disorders.
    FK3453
  • HY-41700R
    D-Alanine (Standard) 338-69-2 98%
    D-Alanine (Standard) is the analytical standard of D-Alanine. This product is intended for research and analytical applications. D-Alanine is a weak GlyR (inhibitory glycine receptor) and PMBA agonist, with an EC50 of 9 mM for GlyR.
    D-Alanine (Standard)
  • HY-44178S
    Diethyl butylmalonate-D9 1189865-34-6 98%
    Diethyl butylmalonate-d9 is the deuterium labeled Diethyl butylmalonate (HY-44178). Diethyl butylmalonate is a competitive inhibitor of succinate dehydrogenase. Diethyl butylmalonate exerts anti-inflammatory effects by inhibiting ROS production. Diethyl butylmalonate also has neuroprotective activity. In addition, Diethyl butylmalonate shows toxicity to T. pyriformis, with its log(IGC50-1) being 0.557. Diethyl butylmalonate can be used in the research of diseases such as Alzheimer's disease.
    Diethyl butylmalonate-D9
  • HY-50722A
    (Rac)-NNC 55-0396 2517420-92-5
    (Rac)-NNC 55-0396 is the racemate of NNC 55-0396 (HY-50722).
    (Rac)-NNC 55-0396
  • HY-66012A
    Proparacaine 499-67-2 98%
    Proparacaine (Proxymetacaine) is a local anesthetic. Proparacaine blocks voltage-gated sodium channels on neuronal cell membranes, thereby inhibiting signal conduction and nociceptive signal transmission. Proparacaine blocks nociceptive signals in the eye and induces ocular muscle relaxation to reduce eye movement during surgery. Proparacaine is used in research related to cataracts.
    Proparacaine
  • HY-69019A
    7-Nitroindazole sodium 161467-34-1 98%
    7-Nitroindazole sodium is a selective and BBB-penetrable inhibitor of nitric oxide synthase (NOS). 7-Nitroindazole sodium can inhibit the activity of central NOS with an IC50 of 0.47 μM in the cerebellum of mice. 7-Nitroindazole sodium has anti-injurious and neuroprotective properties.
    7-Nitroindazole sodium
  • HY-75704A
    Tezampanel hydrate 317819-68-4 98%
    Tezampanel (LY293558) hydrate is a potent, selective and competitive NMDA receptor antagonist. Tezampanel hydrate produces postoperative analgesia in rats. Tezampanel hydrate can be used for neuropathic pain research.
    Tezampanel hydrate
  • HY-76569S
    Desfesoterodine-d5 98%
    Desfesoterodine-d5 (PNU-200577-d5) is the deuterium labeled Desfesoterodine (HY-76569). Desfesoterodine (PNU-200577) is a potent and selective muscarinic receptor (mAChR) antagonist with a KB and a pA2 of 0.84 nM and 9.14, respectively. Desfesoterodine is a major pharmacologically active metabolite of Tolterodine (PNU-200583; HY-A0024) and Fesoterodine (HY-70053). Desfesoterodine improves cerebral infarction induced detrusor overactivity in rats.
    Desfesoterodine-d5
Cat. No. Product Name / Synonyms Application Reactivity